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ABSTRACT
The human immunodeficiency virus type 1 (HIV-1)
regulator Tat is essential for viral replication
because it achieves complete elongation of viral
transcripts. Tat can be released to the extracellular
space and taken up by adjacent cells, exerting
profound cytoskeleton rearrangements that lead to
apoptosis. In contrast, intracellular Tat has been
described as protector from apoptosis. Tat gene is
composed by two coding exons that yield a protein
of 101 amino acids (aa). First exon (1–72aa) is suffi-
cient for viral transcript elongation and second
exon (73–101 aa) appears to contribute to
non-transcriptional functions. We observed that
Jurkat cells stably expressing intracellular Tat101
showed gene expression deregulation 4-fold
higher than cells expressing Tat72. Functional
experiments were performed to evaluate the effect
of this deregulation. First, NF-iB-, NF-AT- and
Sp1-dependent transcriptional activities were
greatly enhanced in Jurkat-Tat101, whereas Tat72
induced milder but efficient activation. Second,
cytoskeleton-related functions as cell morphology,
proliferation, chemotaxis, polarization and actin
polymerization were deeply altered in Jurkat-
Tat101, but not in Jurkat-Tat72. Finally, expression
of several cell surface receptors was dramatically
impaired by intracellular Tat101 but not by Tat72.
Consequently, these modifications were greatly
dependent on Tat second exon and they could be
related to the anergy observed in HIV-1-infected
T cells.
INTRODUCTION
The human immunodeﬁciency virus type 1 (HIV-1)
transcriptional activator (Tat) is essential for viral gene
expression and replication (1). Tat fulﬁls an eﬃcient
viral transcript elongation through the interaction with
the Tat response element (TAR), a stem-loop RNA
located at the 50-end of nascent viral transcripts that
enables the recruitment of cellular factors as P-TEFb to
increase the functional capacity of the RNA polymerase II
(RNAPII) (2). P-TEFb is composed of cyclin T1, which
directly interacts with Tat and permits the binding to TAR
(3), and CDK9, which hyperphosphorylates RNAPII (4).
Other functions have also been attributed to Tat as
enhancing viral reverse transcription (5), mimicking
chemokine functions (6), suppressing antigen speciﬁc
CD8
+ T-cell immune response (7), and regulating host
cell gene expression through binding to canonical
enhancer sequences of cellular transcription factors (8)
or creating a complex interactome formed by several
host cell proteins involved in gene expression regulation
(9). Tat can also be released from infected cells and taken
up by adjacent non-infected cells through receptor-
mediated or adsorptive endocytosis (10,11), acting then
as a secretable growth factor, T-cell activator, and modu-
lator of apoptosis (12,13). However, Tat also shows
non-transcriptional activities as the modulation of
cellular protein synthesis, thereby aﬀecting the metabolism
of host cells (12,14).
Tat coding gene consists of two spliced exons separated
in the HIV-1 genome by more than 2300 nts. After
complete splicing of the viral pre-mRNA, a highly
conserved protein of 101 residues is synthesized (15).
Tat101 is the most common protein in clinical HIV-1
isolates but several laboratory virus strains (LAI, HXB2,
BRU, NL4.3) encode a Tat86 protein (3), a non-natural
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Tat is composed by several domains (Figure 1A): the
cysteine-rich domain [amino acid (aa) 22–37] is required
for Tat transcriptional activity (16); the central domain
(aa 38–48) contains the conserved
36VCFT
39 motif
involved in tubulin binding and apoptosis (17–19), and
the
41KGLGI
45 motif that constitutes the minimal activa-
tion domain together with the cysteine-rich domain (20);
the basic domain (aa 49–57) contains the nuclear localiza-
tion signal
49RKKRRQRRR
57 necessary for binding to
TAR (21,22), Tat cellular uptake (23), and nuclear
translocation (24), and this region is the minimal
neurotoxic region causing cell death (25); the
glutamine-rich region (aa 60–72) has been involved in
Tat-mediated apoptosis of T-cells (26); and ﬁnally, the
second exon (aa 73–101) is the least conserved region
between diﬀerent isolates, with homology below 50%
(Figure 1B). This region contains two main motifs: an
78RGD
80 sequence absent in HIV-2 and SIV (simian
immunodeﬁciency virus) Tat that is involved in cell
adhesion (27); and the
86ESKKKVE
92 motif that has
been described as critical for NF-kB transactivation (28).
The second exon has been involved in several activities as
the cellular uptake of the exogenous Tat (29), apoptosis
through increasing activity of caspase-8 (30,31),
improvement of HIV-1 replication in tissue culture and
primary PBLs (2,28,32), and IL-2 superinduction in
HIV-1-infected T cells after CD3/CD28 co-stimulation
(33). The contribution of the second exon to HIV-1
in vivo replication has also been demonstrated after the
accidental infection of three laboratory workers with the
HXB2 HIV-1 isolate that shows a premature stop codon
at the aa 89. In two of these patients, this mutation
reverted spontaneously yielding a more pathogenic virus
(34,35). These results were also conﬁrmed in four
macaques infected with SIVtat1ex virus that reverted to
wild-type SIV in two of them, correlating with increased
viral load and decreased CD4
+ T-cell count (35).
Both extra and intracellular Tat display the same struc-
ture, but this protein acts diﬀerently when is synthesized
inside the cell during HIV-1 infection than when is
released from infected cells. Intracellular Tat is able to
protect cells from apoptosis (14,36,37), whereas
extracellular Tat is considered a dose-dependent
pro-apoptotic factor (38–41) that contributes to the
acquired immunodeﬁciency syndrome (AIDS)-associated
immunosuppresion and pathologies as Kaposi’s sarcoma,
dementia and degenerative diseases (17,42–44). One
pro-apoptotic mechanism described for extracellular Tat
involves its attachment to microtubules and to the actin
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Figure 1. HIV-1 Tat protein structure. (A) Full-length Tat protein consists of 101aa. Tat ﬁrst exon expands from 1 to 72 residues, while second exon
expands from 73 to 101 residues. Tat complete sequence can be divided into ﬁve conserved domains. A highly conserved motif
41KGLGI
45 located at
the central domain constitutes the minimal activation domain together with both N-terminal acidic and cysteine-rich domains. The highly conserved
motif
49RKKRRQRRR
57 (NLS) located at the basic domain confers Tat the ability to bind TAR and translocate to the nucleus. The second exon
region contains the rather conserved motif
78RGD
80 involved in cell adhesion signal and a partially conserved
86ESKKKVE
92 motif involved in
NF-kB transactivation. (B) Alignment of Tat protein sequences from several clinical isolates shows that the ﬁrst exon is highly conserved amongst
diﬀerent HIV-1 isolates, whereas the second exon shows homology lower than 50%. Sequence names provided correspond to the GenBank accession
number for each sequence. Sequences of Tat101 and Tat72 proteins used in this study are also included.
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dynamics. Cytoskeleton is involved in cell motility, prolif-
eration and intracellular traﬃcking, as well as in cell shape
maintenance and polarity. Actin ﬁlaments, actin-binding
proteins and microtubules are not only essential for
regulating cell death, but also play a major role in
HIV-1 infection. Viral traﬃcking is mediated through
microtubules by retrograde transport, the viral core uses
dynein to move toward the nuclear pore complex (NPC)
(47), and the cytoskeleton reorganization is necessary to
initiate HIV-1-induced membrane fusion, viral assembly
and budding (48). In this context, although intracellular
Tat101 induces down-regulation of several cytoskeletal
proteins, it does not cause cell death (14), suggesting
that intracellular Tat has a role in the modiﬁcation of
the cytoskeleton structure for adapting the host cell to
HIV-1 infection (49).
In the present work, the contribution of intracellular
Tat to changes in the T-cell cytoskeleton structure and
function and the speciﬁc role of the second exon in these
modiﬁcations were analysed by microarrays and func-
tional assays. Deregulation of gene expression was 4-fold
higher in T cells expressing intracellular Tat101 than Tat
truncated at the second exon (Tat72). We prove that the
C-terminus is important for modifying cytoskeleton func-
tions as cell morphology, growth, proliferation, and
chemotaxis, as well as T-cell signalling and activation.
Furthermore, in silico modelling of Tat72 suggests that
the second exon can induce higher aﬃnity or strength in
the binding of Tat to its target sequences or protein
partners.
MATERIALS AND METHODS
Cells
Jurkat cell lines were cultured in RPMI 1640 medium
(Biowhitaker, Walkersville, MD, USA) with 10% fetal
calf serum (PAN Biotech GmbH, Aidenbach, Germany),
2mM L-glutamine, 100mg/ml streptomycin and 100U/ml
penicillin, at 37 C. Jurkat TetOﬀ cell line was purchased
from BD Biosciences Clontech (Mountain View, CA,
USA) and cultured according to manufacturer’s instruc-
tions. Jurkat TetOﬀ cells stably transfected with HIV-1
pTRE2hyg-tat101 (Jurkat-Tat101) or pTRE2hyg-tat72
(Jurkat-Tat72) expression vectors were maintained in
200mg/ml geneticin/G418 (Sigma-Aldrich, St. Louis,
MO, USA) and 200mg/ml hygromycin B (BD
Biosciences Clontech). Tat expression could be stopped
by adding 1mg/ml doxycycline (BD Biosciences
Clontech) in the culture medium for 2 days.
Vectors
Plasmid pCMV-tat101 has already been described by
Arenzana-Seisdedos et al. (50). Complementary DNA
(cDNA) from tat ﬁrst exon (1-219nt; 1–72aa) was
obtained from pCMV-tat101 using speciﬁc
oligonucleotides and cloned in pTRE2hyg vector (BD
Biosciences Clontech) using BamHI/NheI cloning sites
(pTRE2hyg-tat72 vector). Empty pTRE2hyg vector and
pcDNA3.1 vector (Invitrogen, Carlsbad, CA, USA) were
used as negative controls. Long terminal repeat (LTR)-
LUC vector containing the luciferase (LUC) reporter
gene under the control of HIV-1 LTR U3+R region
(LAI strain) was described by Bachelerie et al. (51).
LTR-EGFP vector was generated by cloning the
enhanced green ﬂuorescence protein (EGFP) gene from
pEGFP plasmid (BD Bioscience) into LTR-LUC vector
using AgeI/NotI cloning sites after removing LUC gene.
3kB-LUC vector that contains a LUC gene under
the control of three  kB consensus motifs of the
immunoglobulin k-chain promoter was also described by
Arenzana-Seisdedos et al. (50). NF-AT-LUC has been
described by Northrop et al. (52) and encompasses three
tandem copies of the NF-AT-1 binding site in the
interleukin-2 (IL-2) enhancer. The SP1-LUC plasmid
contains two consensus sequences for SP1 cloned into
the p19LUC vector (53). pSV-b-galactosidase vector,
used as control of transfection eﬃciency, was purchased
from Promega (Madison, WI, USA). Plasmids were
puriﬁed using Qiagen Plasmid Maxi Kit (Qiagen, CA,
USA), following the manufacturer’s instructions.
Reagents and antibodies
Monoclonal antibody against HIV-1 Tat (aa 2–9) was
obtained from Advanced Biotechnologies Inc.
(Columbia, MD, USA). Speciﬁc antibody against the
b-isoform of actin was obtained from Sigma Aldrich (St.
Louis, MO, USA). Antibodies against the chemokine
(C-X-C motif) receptor 4 (CXCR4) conjugated with
phycoerythrin (PE) and against CD4 and CD1a
conjugated with ﬂuorescein isothiocyanate (FITC) were
purchased from BD Biosciences. Antibody against
ezrin-radixin-moesin (ERM) protein family was kindly
gifted by Dr. Francisco Sa ´ nchez-Madrid from Hospital
de la Princesa, Madrid, Spain (54,55). Polyclonal
antibodies against p65/RelA (clone C-20) and against
IkBa (clone C-21) were supplied by Santa Cruz
Biotechnology (Santa Cruz, CA, USA). Polyclonal
antibodies against phosphorylated-NF-kB p65/RelA
(Ser
536) and against phosphorylated-IkBa (Ser
32) were
supplied by Cell Signaling Technology (Danvers, MA,
USA). Secondary antibodies conjugated with horseradish
peroxidase (HRP) were purchased from GE Healthcare
(Uppsala, Sweden). Secondary antibodies conjugated to
Alexa 488 and TexasRed were purchased from
Molecular Probes (Eugene, OR, USA). Stromal
cell-derived factor-1 alpha (SDF-1a)/CXCL12 was used
at 50nM and it was kindly provided by Dr. Franc ¸ oise
Baleux (Institut Pasteur, Paris, France).
Phytohemagglutinin (PHA) was used at 5mg/ml.
Phalloidin conjugated with FITC was purchased from
Invitrogen. Propidium iodide and 40,6-diamidino-
2-phenylindole (Dapi) were obtained from Sigma Aldrich.
Transfection assays
Stable transfection of Jurkat TetOﬀ cells with
pTRE2hyg-tat72 and pTRE2hyg expression vectors was
performed by electroporation with an Easyjet Plus
Electroporator (Equibio, Middlesex, UK). In brief,
5 10
6 cells were collected in 250ml of RPMI without
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electroporation cuvette with 2mm electrode gap
(Equibio). Cells were transfected by two pulses at 280V,
150mF and 330X. After transfection, cells were incubated
in supplemental RPMI at 37 C for 18h and then geneticin
and hygromycin B were added to the culture medium at
50mg/ml each per day until selection. For transient
transfections, 5 10
6 cells were resuspended in 350mlo f
RPMI without supplements and mixed with 5mgo f
plasmid DNA in an electroporation cuvette with 4mm
electrode gap (Equibio). Cells were transfected by one
pulse at 280V and 1500mF. After transfection, cells were
incubated in supplemental RPMI at 37 C for 18h. LUC
and b-Galactosidase activities were assayed using
Luciferase Assay System and b-Galactosidase Enzyme
Assay System (Promega), respectively, according to man-
ufacturer’s instructions. Relative LUC units (RLUs) were
measured in supernatants with a Sirius luminometer
(Berthold Detection Systems, Oak Ridge, TN, USA)
after the addition of the appropriate substrate;
b-Galactosidase activity was measured at 420nm in a
microplate reader Sunrise (Tecan Group Ltd.,
Ma ¨ nnedorf, Switzerland). RLUs were normalized by mea-
suring both b-Galactosidase activity and total protein
concentration by the method of Bradford (56) using a
bovine serum albumin (BSA) standard curve.
HIV-1 infection
Brieﬂy, 10 10
6 of MT-2 cells were incubated with
0.5mg/ml of p24-gag of NL4.3 virus for 2h at gentle
rotation and room temperature. Cells were then
centrifuged at 2500rpm for 30min at 25 C, and washed
ﬁve times with PBS1x. After incubation for 2 or 7 days
post-infection, nuclear protein extracts were obtained as
described by Laı´n de Lera et al. (57) and protein concen-
tration was determined by the method of Bradford using a
BSA standard curve (56).
RT–PCR assays
Total RNA from Jurkat cells was isolated with RNeasy
Mini kit (Qiagen) following manufacturer’s instructions.
Speciﬁc primers for amplifying full-length HIV-1 tat gene
(306bp) were as follows: Tat-s, 50-ATGGAGCCAGTAG
ATCCTA-30; and Tat-as, 50-ATCGCACGGATCTGTCT
CT-30. Primers for amplifying tat ﬁrst exon (219bp) were
the former Tat-s and Tat72-as, containing a stop codon
(underlined text), 50-CTATGCTCTGATAGAGAAGC
T-3. Primers for amplifying human CD4 gene were as
follows: CD4-s, 50-GCACTTGCTTCTGGTGCTGCAA
CT-30, and CD4-as, 50-ACTGAGGAGTCTCTTGATCT
GAGA-30, yielding a fragment of 1,296bp. Primers for
generic ampliﬁcation of human CD1 genes (A, B, C, D,
E) were as follows: CD1-s, 50-AAGTGAAGCCCGAGG
CCTGGCTGT-30, and CD1-as, 50-GTCCTGGCCCTCT
A GACTGCTGTG-30, yielding a fragment of 265bp.
Primers for amplifying human b-actin gene were as
follows: b-actin-s, 50-TCACCCACACTGTGCCCA
TCTA-30, and b-actin-as, 50-AGTTGAAGGTAGTTTC
GTGGAT-30, yielding a fragment of 360bp. RT–PCR
assay was performed by using Qiagen OneStep RT–PCR
Kit (Qiagen). Brieﬂy, the reaction mix contained 10mlo f
buﬀer 5X, 2mM MgCl2, 0.1mM dNTPs, 0.4mM of each
primer pair, and 1ml of Qiagen OneStep RT-PCR enzyme
mix in a ﬁnal volume of 50ml. A total of 5mg of RNA was
added and thermal cycling conditions were as follows: an
initial cycle of 48 C for 45min and 95 C for 10min; 45
cycles of 95 C for 30s, 55 C for 30sec, 72 C for 30s; and a
ﬁnal extension cycle of 72 C for 10min. Ampliﬁed
products were analysed by electrophoresis on 3%
Seakem agarose gel containing 5mg/ml of ethidium
bromide in 0.5x Tris-acetate buﬀer. DNA Molecular
Weight Marker XIV (Roche Applied Science, Barcelona,
Spain) was used as 100bp ladder. BigDye Terminator
Cycle Sequencing Kit (Applied Biosystems, Foster City,
CA, USA) was used for sequencing the ampliﬁed DNA
fragments according to manufacturer’s instructions by
using an ABI Prism 3700 DNA Analyzer (Applied
Biosystems). Densitometry analysis was performed using
Quantity One software (Bio-Rad). Gel bands were
quantiﬁed and background noise was subtracted from
the images. Relative ratio of optical density units was
calculated regarding to the gel band corresponding to
the internal control for each lane and each type of RNA
sample.
Sequence alignment
Thirty Tat protein sequences obtained from diﬀerent
HIV-1 isolates were obtained at random from GenBank
database (58), National Center for Biotechnology
Information (NCBI, Rockville Pike, Bethesda, MD,
USA). These sequences were aligned with those corre-
sponding to Tat101 and Tat72 proteins used in this
study, previously ampliﬁed with speciﬁc primers and
sequenced with BigDye Terminator Cycle Sequencing
Kit (Applied Biosystems). Alignment was performed by
using the Multiple Alignment Construction & Analysis
Workbench (Macaw) software v2.05 (59).
Immunoﬂuorescence assays
For immunoﬂuorescence assays, cells were immobilized in
PolyPrep slides (Sigma-Aldrich) for 15min and then ﬁxed
with 2% paraformaldehyde (PFA)–0.025% glutaral-
dehyde in PBS for 10min at room temperature. After
washing twice with 0.1% glycine/PBS, cells were
permeabilized with 0.1% Triton X-100/PBS for 10min.
Cells were then treated with 1mg/ml NaBH4 for 10min.
Incubation for 1h at room temperature with each primary
and secondary antibodies and subsequent washes were
performed with PBS1x-2% BSA-0.05% saponine buﬀer.
Coverslips were immobilized with 70% glycerol/PBS.
Images were obtained with a Radiance 2100 confocal
microscope (BioRad, Hercules, CA, USA), Leica
TCS-SP confocal microscope (Leica Microsystems,
Wetzlar, Germany) or a Leica DMI 4000B Inverted
Microscope (Leica Microsystems).
Flow cytometry
Cells transiently transfected with vector LTR-EGFP were
analysed on a FACScalibur Flow Cytometer (BD
Biosciences), using CellQuest software (BD Biosciences).
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iodide-negative) cells that also showed the highest ﬂuores-
cent on FL1 green channel (60). For studying changes in
cell morphology, live (propidium iodide-negative) cells
were analysed by their relative size and complexity in
sideward scatter (SSC)/forward scatter (FSC) dot plots.
For staining of cell surface antigens, cells were washed
with PBS1x and then incubated for 20min at 4 C with
speciﬁc antibodies or the appropriate isotype control.
Cell proliferation assays
Cell proliferation was measured with CellTiter-96
Aqueous Non-Radioactive Cell Proliferation Assay
(Promega) accordingly to manufacture’s instructions.
Brieﬂy, 2 10
4 cells per well were cultured in a 96-well
plate in the absence of any stimuli or with 5mg/ml PHA
for 72h. Compound 3-(4,5-dimethylthiazol-2-yl)-
5(3-carboxy methonyphenol)-2-(4-sulfophenyl)-2H-
tetrazolium (MTS) was mixed with phenazine
methosulfate solution and then added to the culture
medium. Absorbance was measured at 490nm after 3h
incubation. Proliferation rate for each cell type in
response to PHA was compared with their proliferation
rate in the absence of stimulus.
Analysis of cytoskeleton structure and function
Migration assays were performed in Transwell plates
(Costar, Cambridge, MA, USA) of 6.5-mm diameter
with 5mm-pore ﬁlters. Brieﬂy, 10
5 cells diluted in
complete medium were plated in the upper compartment,
ﬁlling the lower compartment with medium alone or with
SDF-1a/CXCL12 at 50nM. Plates were then incubated
for 2h at 37 C with 5% CO2. Migrated cells were collected
from the lower compartment and counted by ﬂow
cytometry for 1min sharp. Migration ratio represents
the ratio between the migration input in the presence or
absence of SDF-1a/CXCL12. For cell polarization assays,
Jurkat cells adhered to ﬁbronectin (75mg/ml) pre-treated
coverslips were cultured for 45min at 37 C in the absence
or presence of SDF-1a/CXCL12. Cells were stained with
an antibody against ERM proteins and a secondary
antibody conjugated with TexasRed. Images were
acquired with a Leica TCS-SP confocal microscope
(Leica Microsystems). Polarization rate represents the
ratio percentage between the number of polarized cells
and the number of total cells counted in 15 diﬀerent
microscope ﬁelds. For F-actin polymerization assays,
cells cultured during 15s at 37 C in the absence or
presence of SDF-1a/CXCL12 were simultaneously ﬁxed
and permeabilized with 2% PFA and 0.1% Trito ´ n
X-100. Phalloidin conjugated with FITC (6U/ml) was
then added during 15min at 37 C. Phalloidin binds at
the interface between F-actin subunits, avoiding its
depolymerization. The amount of polymerized F-actin
was determined by ﬂow cytometry.
Immunoblotting assays
Cytosolic and nuclear protein extracts were obtained as
described by Laı´n de Lera et al. (57) and protein concen-
tration was determined by the Bradford method using a
BSA standard curve (56). Ten micrograms were
fractionated by sodium dodecyl sulfate-polyacrilamide
gel electrophoresis (SDS-PAGE) and transferred onto
Hybond-ECL nitrocellulose paper (GE Healthcare).
After blocking and incubation with primary and second-
ary antibodies, proteins were detected with SuperSignal
West Pico Chemiluminescent Substrate (Pierce,
Rockford, IL, USA). Antibodies against histone H1
(clone AE-4) and NF-kB p105 (clone H-119) provided
by Santa Cruz Biotechnology were used as internal
control for purity of nuclear and cytosolic extracts, respec-
tively. Images were acquired in a BioRad Geldoc 2000
(BioRad) and densitometry analysis was performed
using Quantity One software (Bio-Rad). Relative ratio
of optical density units was calculated regarding to the
gel band corresponding to the internal control for each
lane and each type of protein extracts after subtracting
the background noise.
DNA aﬃnity immunoblotting assay
The DNA aﬃnity immunoblotting (DAI) assay was per-
formed as previously described by Liu et al. (61) with
minor modiﬁcations. Brieﬂy, 100mg of nuclear protein
extracts from Jurkat TetOﬀ, Jurkat-Tat72 and
Jurkat-Tat101 cells were incubated at 4 C for 30min
with 25nM of a 50-end-labelled biotin probe that
contains the double  kB consensus motif located in the
HIV-1 LTR promoter (50-AGCTTACAAGGGACTTTC
CGCTGGGGACTTTCCAGGGA-30), with this probe
mutated at the  kB consensus sites (50AGCTTACAA
CTCACTTTCCGCTGCTCACTTTCCAGGGA) or
with a probe that contains the estrogen receptor (ER)
DNA element, a non-related NF-kB gene (62).
Biotin-probe/protein complexes were captured by
incubating with streptavidin agarose resins (Pierce) at
4 C for 30min and then collected by centrifugation at
3000g for 10min. Protein complexes were fractionated
by SDS-PAGE and the presence of p65/RelA protein
bound to DNA probes was detected by immunoblotting
with a speciﬁc antibody (clone C-20; Santa Cruz
Biotechnology). As internal control 10mg of protein
were separated before adding each probe and resolved
by Western-blot using an antibody against b-actin
(Sigma-Aldrich).
Microarrays assays
Total RNA from Jurkat cells was isolated with RNeasy
Maxi kit (Qiagen) following manufacturer’s instructions.
One-Color Microarray-Based Gene Expression Analysis
Protocol (Agilent Technologies, Palo Alto, CA, USA)
was used to amplify and label RNA. Brieﬂy, 1mgo f
total RNA was reverse transcribed using T7 promoter
primer and the Moloney murine leukemia virus
(MMLV) reverse transcriptase (RT). cDNA was then con-
verted to antisense RNA (aRNA) by using T7 RNA
polymerase that ampliﬁes target material and incorporates
cyanine 3 (Cy3)-labelled CTP simultaneously. Samples
containing 1.65mg of Cy3-labeled aRNA were hybridized
to a Whole Human Genome Microarray 4 44K
(G4112F, Agilent Technologies) for 17h at 65 Ci na
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Technologies) set to 10rpm in a ﬁnal concentration of
GEx Hybridization Buﬀer HI-RPM 1x (Agilent
Technologies). Arrays were washed and dried out using
a centrifuge according to manufacturer’s instructions
(One-Color Microarray-Based Gene Expression
Analysis, Agilent Technologies). Arrays were scanned at
5mm resolution on an Agilent DNA Microarray Scanner
(G2565BA, Agilent Technologies) using the default
settings for 4 44K format one-color arrays. Images
provided were analysed using Feature Extraction
software v9.5.3.1 (Agilent Technologies).
Statistical analysis
Data ﬁles from Feature Extraction software were
imported into GeneSpring GX software v9.0 (Agilent
Technologies). Quantile normalization was performed
and expression values (log2 transformed) were obtained
for each probe. Probes were also ﬂagged as Present,
Marginal or Absent using GeneSpring default settings.
Probes that were ﬂagged as Present or Marginal in all
three replicates for the two experimental conditions to
be compared on each contrast were selected for further
analysis. These ﬁltered data were loaded into SAM
(Signiﬁcance Analysis of Microarrays) software for
genomic expression data mining (63). SAM uses the
false discovery rate (FDR) and q-value method as
described by Storey (64). Expression ratios (log2) were
calculated using control cells values as baseline. For con-
sidering a fold change as statistically signiﬁcant, the
q-value cutoﬀ was set at 5%.
Functional and canonical pathway analyses
Functional and canonical pathway analyses of speciﬁc
gene datasets coming from SAM analysis were performed
by using Ingenuity Pathway Analysis (Ingenuity Systems,
Redwood City, CA, USA). Functional analysis was per-
formed to identify functions and/or diseases that were
most signiﬁcant to the dataset. All genes from the
dataset that were associated with biological functions
and/or diseases in the Ingenuity knowledge database
were considered for the analysis. B-H Multiple Testing
Correction p-value test (65) was used to calculate the p-
value for determining the probability that each biological
function and/or disease assigned to the dataset was due to
chance alone. Canonical pathway analysis identiﬁed from
the Ingenuity Pathway Analysis library those pathways
that were more signiﬁcant to the dataset. All genes
associated with a canonical pathway in the Ingenuity
knowledge base were considered for the analysis. The sig-
niﬁcance of the association between the dataset and the
canonical pathway was measured in two ways: ﬁrst, the
ratio of the number of genes from the dataset that map to
the pathway divided by the total number of molecules that
exist in the canonical pathway; and second, the B-H
Multiple Testing Correction p-value test was used to cal-
culate a p-value to determine the probability that the asso-
ciation between the genes in the dataset and the canonical
pathway was due to chance alone.
Tat in silico modelling
Tat72 protein model was constructed by homology mod-
elling based on the nuclear magnetic resonance (NMR)
spectra structure of unbound HIV-1 Tat with 86 residues
from HIV-1 BRU isolate (PDB code: 1jfw) (66) plus
residues 49–68 from EIAV Tat protein bound to TAR/
P-TEFb complex (PDB code: 2w2h) (67) using Modeller
9v4 software (68). Electrostatic potentials were calculated
using the Adaptive Poisson–Boltzmann Solver (APBS)
software (69) and displayed at the solvation accessible
surface with Pymol software (http://www.pymol.org/).
Tat interaction with TAR/cyclin T1/CDK9 complex was
modelled by substituting EIAV Tat from 2w2h structure
by Tat72 model, after structural alignment with
Matching Molecular Models obtained from Theory
(MAMMOTH) software (70,http://ub.cbm.uam
.es/software.php?lang=en). CDK9 structure was incorpo-
rated to the complex, mimicking the interaction with
cyclin T1 observed in PDB structure 3blh (71), after
superposition of cyclinT1 from both complexes with
MAMMOTH software. It was necessary to apply subtle
deformations to modelled Tat72 using the sculpting tool
of Pymol software in order to avoid collisions with cyclin
T1. The complex was energy minimized with the
SANDER module from the Assisted Model Building
with Energy Reﬁnement (AMBER) v8 package of molec-
ular simulation programs (http://ambermd.org/).
Hydrogen atom positions and standard atomic charges
and radii were assigned according to Amber ﬀ99 force
ﬁeld.
RESULTS
Analysis of Tat72 expression in stably transfected
Jurkat cells
Jurkat TetOﬀ cells stably transfected with gene codifying
Tat72 protein were generated as described previously by
Coiras et al. (14) for the stable Jurkat-Tat101 cell line . All
ﬁgures show the means of data or representative experi-
ments performed with two independent populations of
Jurkat-Tat72 and Jurkat-Tat101 cells. No clones were
used. Due to the high mortality induced by long-term
treatment with doxycycline, Jurkat TetOﬀ stably
transfected with empty plasmid pTRE2hyg were mostly
used as negative control.
Total RNA from stably transfected Jurkat-Tat72 cells
was analysed by RT–PCR. A single band of the expected
size (219nt) was observed, in comparison with the
full-length Tat gene (306nt) detected in Jurkat-Tat101
cells (Figure 2A). RT–PCR assay speciﬁcity was proved
by automatic sequencing. Expression of Tat protein in
both Jurkat-Tat101 and Jurkat-Tat72 cells was highly
stable, with comparable half-life, and very similar to a
real infection (Figure 2B), as was determined previously
by Coiras et al. (14). Jurkat-Tat72 cells were also analysed
by immunoﬂuorescence to determine Tat subcellular local-
ization. This truncated protein showed a predominant
nuclear localization, similarly to Tat101 (Figure 2C).
The percentage of cells that were expressing Tat72 or
3292 Nucleic Acids Research, 2010,Vol.38, No. 10Tat101 within the whole population was calculated by
transient transfection of vector LTR-EGFP and ﬂow
cytometry analysis. Jurkat-Tat72 cells were a mixed pop-
ulation in which 33% of cells showed very high expression
of Tat (Figure 2D). The role of Tat in LTR
transactivation was also conﬁrmed by transfecting
LTR-EGFP in the presence of doxycycline (data not
shown).
Transcriptional activity induced by Tat101 or Tat72
intracellular expression
Jurkat-Tat101 and Jurkat-Tat72 were transiently
transfected with vector LTR-LUC and LUC activity was
measured after 18h. Both Tat72 and Tat101 were able to
promote the transactivation of the HIV-1 LTR, although
full-length Tat was slightly more eﬃcient in LTR
transactivation than Tat72 (Figure 3A). Role of Tat in
LTR transactivation was assessed by treatment with
doxycycline. Basal transcriptional activity due to NF-kB
exclusively was also evaluated by transient transfection of
vector 3kB-LUC. kB-dependent activity was also higher in
Jurkat-Tat101 than in Jurkat-Tat72 cells (Figure 3B).
NF-kB-dependent synthesis of LUC was conﬁrmed by
simultaneous co-transfection of vector CMV-IkBa to
produce the over-expression of IkBa, the main inhibitor
of NF-kB. Analysis by immunoblotting of nuclear local-
ization of the main active NF-kB protein, p65/RelA,
showed that while this protein remained unchanged in
Jurkat-Tat72, total p65/RelA was 2.7-fold increased in
Jurkat-Tat101 and Ser
536-phosphorylated p65/RelA was
1.6-fold increased (Figure 3C). Cytosolic IkBa was
mainly increased in Jurkat-Tat101 cells, but
Ser
32-phosphorylated IkBa was more than 2-fold
increased in both cell types (Figure 3D). Because IkBa
resynthesis is dependent on the NF-kB activity, higher
quantity of IkBa proved the existence of high NF-kB
activity in Jurkat-Tat101 and Jurkat-Tat72. Besides,
IkBa phosphorylated at Ser
32 is susceptible to be
degraded in the proteasome, letting active NF-kB free to
be translocated to the nucleus. NF-kB activity in
Jurkat-Tat72 and Jurkat-Tat101 was measured by DAI
assay using a speciﬁc probe containing both -kB consensus
sites located at the HIV-1 LTR promoter. Free NF-kB
able to bind the promoter was more than 2-fold increased
in Jurkat-Tat72 and more than 3-fold increased in
Jurkat-Tat101 when compared with control cells
(Figure 3E). NF-AT- and Sp1-dependent transcriptional
activities were also analysed by transient transfection of
vectors Sp1-LUC (Figure 3F) or NF-AT-LUC
(Figure 3G). Both NF-AT and Sp1 activity were greatly
enhanced in Jurkat-Tat101 cells, whereas Jurkat-Tat72
showed similar activity than control cells. Same results
were obtained when Jurkat-Tat cells were treated with
doxycycline immediately after transfection (data not
shown).
Bioinformatics analysis and microarray data clustering
Gene expression patterns of total RNA from
Jurkat-Tat101 and Jurkat-Tat72 cell lines from three inde-
pendent extractions were examined using whole human
genome microarrays containing 44000 probes represent-
ing 41000 human genes and transcripts. Due to the
high toxicity of long-term treatment with doxycycline,
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Figure 2. Characterization of Jurkat-Tat72 cell line. (A) Analysis of
mRNA expression for tat gene in Jurkat-Tat101 cells (306nt) and
Jurkat-Tat72 cells (219nt) by RT–PCR. Jurkat TetOﬀ-pTRE2hyg
cells were used as negative control. 100bp DNA ladder was used as
molecular marker. (B) Tat protein expression was analysed in 150mgo f
nuclear protein extracts from Jurkat-Tat101 (lane 2) and Jurkat-Tat72
(lane 3) by immunoblotting using a monoclonal antibody against Tat
(aa 2–9) and compared with the expression of Tat in MT2 infected with
NL4.3 for 2 and 7 days (lanes 4 and 5). Jurkat TetOﬀ-pTRE2hyg cells
were used as negative control. Histone H1 was used as internal loading
control. Gel bands were quantiﬁed by densitometry and background
noise was subtracted from the images. Relative ratio of optical density
units was calculated regarding to the gel band corresponding to the
internal control for each lane and for each protein extract.
(C) Subcellular localization of Tat was analysed by immunoﬂuorescence
assay in Jurkat-Tat72 and Jurkat-Tat101 using an antibody against Tat
and a secondary antibody conjugated with Alexa 488. Dapi was used
for nuclear staining. Images were captured by ﬂuorescence microscopy.
(D) Analysis of percentage of cells within the whole population
expressing high amounts of Tat was performed by ﬂow cytometry
18h after transfection of Jurkat-Tat72 and Jurkat-Tat101 cells with
LTR-EGFP vector. Histograms show one representative experiment
selected from three independent experiments. EGFP expression from
control cells was used as basal ﬂuorescence (continuous line)
compared to EGFP expression from Jurkat-Tat72 or Jurkat-Tat101
(discontinuous line). Percentage of Tat activity was calculated by sub-
tracting the EGFP expression corresponding to control cells from the
EGFP expression for each Tat-expressing cell line.
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Figure 3. HIV-1 LTR transactivation by Tat intracellular expression. (A) Basal LTR-dependent transactivation activity was measured in
Jurkat-Tat72 and Jurkat-Tat101 by transient transfection of LTR-LUC in the absence of stimulus or after treatment with 1mg/ml doxycycline
for 18h to inhibit Tat expression. Fold mean of RLUs corresponding to three independent experiments was represented as a bar diagram. Lines on
the top of the bars correspond to the standard deviation (SD). (B) NF-kB-dependent transactivation activity was measured by transient transfection
of Jurkat-Tat72 and Jurkat-Tat101 with 3kB-LUC in the absence of stimulus. Speciﬁcity of NF-kB-dependent transactivation was assessed by
co-transfection of CMV-IkBa. Co-transfection of pcDNA3 vector was used as negative control. Fold mean of RLUs corresponding to three
independent experiments is represented and lines on the top of the bars correspond to SD. (C and D) NF-kB activation was also analysed by
immunoblotting of 30mg of nuclear protein extracts, using an antibody against total p65/RelA or Ser
536-phosphorylated p65/RelA (C); and by
immunoblotting of 30mg of cytosolic protein extracts, using an antibody against total IkBa or Ser
32-phosphorylated IkBa (D). Histone H1 was used
as internal loading control of nuclear protein extracts and NF-kB p105 was used as internal loading control of cytosolic protein extracts. Gel bands
were quantiﬁed by densitometry and background noise was subtracted from the images. Relative ratio of optical density units was calculated
regarding to the gel band corresponding to the internal control for each lane and for each protein extract. (E) NF-kB activity was further
analysed in Jurkat-Tat72 and Jurkat-Tat101 in comparison with control cells by using DAI assay. Nuclear protein extracts were incubated with
a speciﬁc probe containing two -kB consensus sites labelled with biotin. After immunoprecipitation with an antibody against p65/RelA, protein/DNA
complexes were puriﬁed, analysed by SDS-PAGE and immunoblotted with an antibody against p65/RelA. Non-related ER DNA element and
mutated -kB probes were used as control of speciﬁcity. Gel bands were quantiﬁed by densitometry and background noise was subtracted from the
images. Relative ratio of optical density units was calculated regarding to the gel band corresponding to the internal control for each lane and for
each sample. (F and G) Sp1- and NF-AT-dependent transactivation activity was measured by transient transfection of either Sp1-LUC or
NF-AT-LUC plasmid. Fold mean of RLUs corresponding to three independent experiments is represented and lines on the top of the bars
correspond to SD. pSV-b-galactosidase vector was used as transfection internal control.
3294 Nucleic Acids Research, 2010,Vol.38, No. 10Jurkat TetOﬀ cells stably transfected with empty
vector pTRE2hyg were used as control of basal expres-
sion. After ﬁltering the scanned images, 25069 and
25863 gene probes were considered for statistical
analysis for the Jurkat-Tat101 versus control compari-
son and the Jurkat-Tat72 versus control comparison,
respectively. Expression values (log2 transformed)
were obtained for each probe in three replicates for
all cell types. Expression ratios (log2) were calculated
using control cells values as baseline. Only probes with
q-value <5% and fold change >2o r< 2 were considered
as statistically signiﬁcant. These statistical analysis crite-
ria yielded 1079 and 274 gene probes for
Jurkat-Tat101 versus control and Jurkat-Tat72 ver-
sus control comparisons, respectively. These results were
summarized in a Venn diagram (Figure 4A). Within
these signiﬁcant gene probes, 111 genes located at
the overlapped area were deregulated in both
Jurkat-Tat101 and Jurkat-Tat72 cell lines. Ontological
analysis of gene expression data suggested that some
essential cellular functions were changed in
Jurkat-Tat101, being this change signiﬁcantly lower in
Jurkat-Tat72 (Figure 4B). Abbreviated grouping of
deregulated genes shorted by fold change and indicating
their biological functions, is given in Table 1, panel A
(Jurkat-Tat101 versus control) and panel B
(Jurkat-Tat72 versus control).
Within the essential functions potentially modiﬁed by
the stable intracellular expression of Tat are noticeable
those related to the cytoskeletal structure, as cellular
movement, growth and proliferation, apoptosis and cell
morphology. However, diﬀerences in gene expression
only reﬂect diﬀerences in RNA levels. Accordingly,
several experiments were performed to prove that the
related cellular functions were modiﬁed.
Cellular morphology and growth of Jurkat-Tat101 and
Jurkat-Tat72 cells
Jurkat-Tat101 and Jurkat-Tat72 cells were analysed by
ﬂow cytometry to determine diﬀerences in cell shape.
Jurkat-Tat72 showed similar size (FSC) and complexity
(SSC) than control cells, but Jurkat-Tat101 population
was scattered, being more than 11% of the population
bigger and more complex (Figure 5A). These results
were conﬁrmed by immunoﬂuorescence analysis using an
antibody against b-actin (Figure 5B). Jurkat-Tat101 cells
presenting bigger size were also expressing higher quantity
of nuclear Tat (Figure 5C).
It was hypothesized that the modiﬁcation in cell
shape could impair the migration capacity of these
cells. Accordingly, cell proliferation assays were per-
formed in response to the mitogen phytohemagglutinin
(PHA). All cell types showed a similar growth rate
in the absence of stimulus, but proliferation upon
PHA treatment was rather impaired in Jurkat-Tat101
cells in comparison with both Jurkat-Tat72 and control
cells, which showed a similar proliferation rate
(Figure 5D).
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Figure 4. Gene expression and bioinformatics analysis. (A) Gene
expression patterns of Jurkat-Tat101 and Jurkat-Tat72 were
compared with control cells. Data were considered statistically signiﬁ-
cant when q-value was <5% and fold change >2o r< 2. These ﬁlter-
ing criteria yielded 1079 analysable gene spots for Jurkat-Tat101 versus
control, and 274 analysable gene spots for Jurkat-Tat72 versus control.
These results are summarized in a Venn diagram. The overlapped area
represents 111 genes that were deregulated in both cell lines.
(B) Analysis of functional and canonical pathways for speciﬁc gene
datasets generated with the B-H Multiple Testing Correction p-value
determined that all cellular functions were mostly altered in
Jurkat-Tat101. Data representing the  log(B–H p-value) are shown
in a histogram for Jurkat-Tat101 versus control and Jurkat-Tat72
versus control comparisons.
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Gene q-value
(%)
Fold
change
Biological function
Panel A: Tat101 versus TetOﬀ (206 genes)
DOCK3 0.0000 69.9473 CMO
SPRY2 0.0000 30.5898 CCS
BANK1 0.0000 25.7293 CS, MT
FGF9 0.0000 23.5740 CCS
FGFR1 0.0000 13.8021 CD, PTM
TNFRSF10A 0.0000 13.5106 CGP
ACVR2A 0.0000 13.4285 CD, GE
CXCR3 0.0000 13.0340 CM, CCS, CS, MT, CD
TNF 0.0000 10.9776 CM, CGP, CCS, CS, MT,
CD, CMO, GE, PTM
SMAD7 0.0000 10.0787 CM, CGP, CD
ARHGEF12 0.0000 9.8740 CS, MT
CCND2 0.0000 9.6583 CM, CGP, PTM
DLL1 0.0000 8.0282 CM
ITGA6 0.0000 7.3254 CM, CMO, PTM
MIA 0.0581 6.5467 CMO
ACVRL1 0.0000 6.3652 CD, CMO, GE
PTPRJ 0.0000 6.1953 CGP, CCS, CS, MT,
PTM
IL15 0.0000 6.1378 CM, CGP, CCS, CD,
CMO, GE
DSP 0.0000 5.7371 CM
SIRPA 0.0000 5.5021 CM, CGP, CCS, CS, MT,
CMO
PAWR 0.0000 5.0122 CGP, CD
XBP1 0.0000 4.9912 CD
ACCN1 0.0000 4.9832 MT, CMO
RETN 0.0000 4.9640 CMO
MLLT4 0.0977 4.9247 CCS
HHEX 0.0000 4.8783 CM
FZD1 0.0000 4.2705 CM, CCS
CCND1 0.0000 4.2609 CM, CD, CMO, PTM
GAD1 0.0000 4.1476 CGP
S100P 0.0000 4.0036 CM, CD
HDC 0.0581 3.8376 CS, MT
APP 0.0000 3.8293 CGP, CCS, CS, MT, CD,
CMO, GE, PTM
JUP 0.0000 3.6628 CM, CD
FXYD2 0.0000 3.6605 MT
CX3CR1 0.0000 3.6179 CS, MT
CEBPD 0.0000 3.3882 CM
PAX6 0.0000 3.2762 CMO
IGF2 0.0581 3.1454 CM, CCS, CS, CD, CMO
GPR132 0.0000 3.0128 CS, MT, CD, CMO
TRIO 0.0000 2.9790 CM, CMO
PTK2 0.5436 2.9777 CM, CD, CMO, PTM
S100B 0.0977 2.9545 CD
NRP1 0.0000 2.9254 CM, CCS
WNT10A 0.0977 2.8577 CCS
SCNN1A 0.0000 2.8546 MT
CD37 0.0977 2.8398 CGP
HPSE 0.0977 2.8313 CM
MBP 0.0000 2.8159 CGP, CCS, CS, MT
TBC1D9 0.0581 2.8141 CD
PROK2 0.0581 2.7223 CS, MT, CD
PERP 0.0000 2.7149 CD
LFNG 1.3632 2.7143 CGP, CCS
NQO1 0.6779 2.6456 CD
FLT1 0.5049 2.6361 CM, CD
FBLIM1 0.0000 2.6094 CMO
GRAP2 0.0000 2.5973 CGP, CCS, CS, MT, CD
PTPRG 0.0977 2.5663 CD
PTK6 0.0000 2.5375 PTM
TMOD1 0.0581 2.5328 CS
NKX3-1 0.0000 2.5054 CD
CLCF1 0.5850 2.4900 CM, CD, PTM
CORT 0.6779 2.4790 CS
BCL3 0.6779 2.4757 CM, CD, CMO
(continued)
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Gene q-value
(%)
Fold
change
Biological function
BMP4 0.0977 2.4662 CGP, CD, CMO, PTM
PECAM1 0.0000 2.4378 CM, CGP, CCS, CS, MT,
CD, CMO, PTM
PMP22 0.0977 2.4255 CMO
CXCR7 0.6779 2.4080 CM, CD
MAP3K8 1.3632 2.4064 CD
LGALS1 0.0581 2.3847 CM, CGP, CS, MT, CD,
PTM
LRP5 0.0000 2.3793 CS
KCNN4 0.1806 2.3744 CGP, MT, CMO
TNFRSF8 1.3632 2.3604 CGP, CS, MT, CD
VASP 0.5049 2.3203 CMO
RASGRP2 0.0581 2.3155 CM
WNT11 0.0581 2.2957 CCS, CD
PHLDA1 0.0581 2.2595 CMO
PPP1R9B 0.0000 2.2537 PTM
ROR2 2.3760 2.2360 CD
IGF1R 3.5372 2.2068 CM, CD, CMO, PTM
PTPRE 0.0000 2.2041 CMO
LIF 0.1806 2.2017 CM, CGP, CCS, CD,
CMO, GE, PTM
ANTXR2 0.0581 2.1844 CD
CDKN1A 0.5436 2.1785 CM, CGP, CCS, CD,
CMO
WNT5A 0.0581 2.1659 CM, CCS, CS, MT, CMO
NCR2 0.5436 2.1629 CCS
RGS17 0.0977 2.1543 CS, MT
TGFBR1 0.0000 2.1529 CM, PTM
CD7 0.1806 2.1243 CCS, PTM
FSTL1 0.0581 2.0666 CM
NFE2 0.5850 2.0597 CD, CMO
TWIST1 0.6779 2.0249 CM, CD, CMO
TGFA 0.6779 2.0236 CM, CS, CD, CMO, PTM
ARHGEF4 0.5850 2.0150 CMO
SMAD1 0.1806 2.0123 CD, CMO, GE
FAT 0.8114 2.0006 CCS
RUNX1 0.5049 1.9918 CM, CD
ITGB2 0.0581 1.9564 CM, CGP, CCS, CS, MT,
CD, CMO, PTM
ELMO1 0.0695  2.0029 CM
IL9R 0.0695  2.0726 CGP
TSLP 0.8114  2.0870 CM, CGP, CCS, CD
PDCD1 0.5850  2.0870 CGP
EPAS1 0.5850  2.0994 CM
CTSS 0.0695  2.1229 CM
MT1E 0.5436  2.1423 CS
SELL 1.7291  2.1700 CM, CGP, CCS, CS, MT,
CMO, PTM
HR 0.1075  2.1723 CGP
EFNA1 0.6779  2.2013 CM, CGP, CCS, CD,
CMO, PTM
HES1 0.5850  2.2032 CD
ABCC8 2.3760  2.2034 CS, MT
IRS1 0.1806  2.2331 CS, CD, CMO
GUCY1A3 0.0695  2.2352 CS
FABP6 3.5372  2.2553 CD
GZMB 1.3632  2.2585 CM, CD
HCK 0.5850  2.2641 CM, CGP, CS, MT, CD,
CMO, PTM
ITGAL 1.7291  2.2834 CM, CGP, CCS, CS, MT,
CD, CMO
ITGA4 0.0000  2.3010 CM, CGP, CCS, CMO
CD79B 0.1075  2.3038 CS, MT, PTM
PRKCE 0.0695  2.3104 CM, CD, CMO, PTM
TIMP2 0.0695  2.3171 CM, CD, CMO
RAG1 0.0695  2.3211 CGP, CD
CCL20 0.0000  2.4262 CM, CCS, CS, MT
CSTA 0.0000  2.4263 CM
STAM 0.1806  2.4309 CGP
(continued)
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KCNJ10 0.1075  2.4497 MT, CMO
B3GNT2 0.0000  2.4822 CGP, CS, MT
GNG4 3.5372  2.5025 CS, MT
FGF7 0.1075  2.5167 CM, CS, CD, CMO, PTM
CFTR 0.0000  2.5366 CM, CCT
ATP6V0A4 0.1075  2.5912 MT, CMO
S100A4 0.1075  2.6105 CS
FPR1 0.0000  2.6130 CS, MT
GRB10 0.0695  2.6232 CCS
CCR7 0.1075  2.6247 CM, CS, MT
TRIM63 0.1075  2.6643 CMO
NMU 1.7291  2.7021 CS, MT
PIK3R1 0.1075  2.7851 CGP, CS, MT, CD, CMO
GPR44 0.0695  2.7906 CS, MT, CD
RB1 0.0000  2.8094 CD, CMO
LMNA 0.0000  2.8471 GE
ITK 0.0695  2.9301 CM, CGP, CCS, CS, MT,
CD
MCAM 0.5850  3.0580 CM, CS, CD
GFRA1 0.1075  3.0751 CD, CMO
NTS 0.0000  3.1310 CS, MT
NR4A1 1.3632  3.2485 CD
ATP4A 0.5850  3.4143 CMO
KCNMB1 0.0000  3.4696 MT
MAP3K13 0.0695  3.4853 PTM
PLCE1 0.5049  3.5354 CS, MT
VPREB1 0.1075  3.5851 CS, MT
AP3B1 0.0000  3.7879 CM
CD44 0.0000  3.8206 CM, CGP, CCT, CS, MT,
CD, CMO, PTM
CCR1 0.1806  3.9116 CM, CCS, CS, MT, CD,
PTM
SLC4A4 0.0000  3.9828 MT
EGR1 1.3632  3.9945 CM, CGP, CD, CMO
ITGA1 0.0000  4.0147 CM
MT1F 0.0000  4.0571 CS, CMO
CADM1 0.1806  4.0804 CGP, CD, CMO
PCSK5 0.0000  4.0960 CCS
DTX1 0.0000  4.1117 CM
RELN 0.0695  4.2063 CCS, CMO, PTM
KCNMA1 0.0695  4.2665 MT
TNFSF10 0.0000  4.3763 CD, CMO
DPP4 0.0000  4.4864 CM, CGP, CD, CMO
RORC 0.0000  4.4933 CGP, CD
SLC12A6 0.0000  4.6417 CM
TCF7 0.0000  4.6828 CGP, CD
BCL11A 0.0000  5.0001 CM
SLAMF1 0.0000  5.1061 CGP, CCS
ICOS 0.0000  5.1255 CGP, CCS, CS, MT, CD
JAG2 0.0000  5.1566 CD
ID1 0.0000  5.2064 CM
NR2F2 0.0000  5.2476 GE
CHFR 0.0000  5.3593 CM, CD
CD1D 0.0000  5.4319 CM, CGP, CCS
CD48 0.0000  5.5570 CM, CGP, CCT, PTM
NEDD9 0.0000  5.5865 CM, CCS
IL4 0.0000  6.0807 CM, CGP, CCS, CS, MT,
CD, CMO, GE, PTM
CR2 0.0000  6.6133 CGP, CCS, CS, MT, CD
TSHR 0.0000  6.7482 CM, CCS, CS, MT, GE
KCNN3 0.0000  7.0343 MT
TXK 0.0000  7.4895 CM, CGP, CCS, CS, MT
ADCYAP1 0.0000  7.5936 CM, CGP, CCS, CS, MT,
CD, CMO
CD84 0.0000  9.5274 CGP
TRAT1 0.0000  10.6097 CS, MT
RGMA 0.0000  11.4124 GE
RUNX2 0.0000  11.8309 CM
EGR3 0.0000  12.9862 CM, CGP, CCS, CD
(continued)
Table 1. Continued
Gene q-value
(%)
Fold
change
Biological function
EGR2 0.0695  13.3176 CM, CCS
PGDS 0.0000  14.6184 CGP
TPO 0.0000  15.4908 CGP, CCS
UCP1 0.0000  15.7752 MT
VIPR2 0.0000  16.6340 CCS, CS, MT
CA9 0.0000  16.8151 CD
PDGFC 0.0000  19.6580 PTM
TRPM6 0.0000  19.7265 CGP
CD1A 0.0000  22.4952 CCS
CCR9 0.0000  24.7316 CM, CS
CD40LG 0.0000  36.2996 CM, CGP, CCS, CD,
CMO
CD1B 0.0000  38.1758 CCS
CD1C 0.0000  40.6670 CCS
CD1E 0.0000  80.3854 CCS
Panel B: Tat72 vs TetOﬀ (65 genes)
CFTR 0.0000 160.8373 CM, CCS, CMO
MARCKS 0.0000 32.3120 CMO
SDC2 0.0000 29.7805 CCS, CD, CMO
TRPS1 0.0000 14.5347 CD
ALDH1A1 0.0000 13.0023 CD
HBD 0.0000 10.6574 CMO
CXCL3 0.0000 7.4230 CM, CCS, CS, MT, CD
PTPRM 0.0000 7.1377 CCS, CD
CD34 0.0000 5.4317 CM, CCS
SPRY2 0.0000 4.0485 CCS, CMO
SLAMF7 0.0000 3.8425 CGP
NPHS1 0.0000 3.7287 CD
CXCL2 0.0000 3.5827 CM, CCS, CS, MT
NR2F2 0.5734 3.5739 GE
PPARG 0.0000 3.4712 CM, CCS, CD, CMO, GE
EFNB2 0.0000 2.9712 CCS, CD
AIFM3 3.0052 2.9543 CD
PPP2R2B 0.0000 2.8863 CD
IL4 1.3733 2.8557 CM, CGP, CCS, CS, MT,
CD, CMO, GE
ALDH1A2 0.0000 2.8421 CD
MIA 1.6513 2.7800 CD, CMO
ANGPT1 1.6513 2.7136 CCS, CD, CMO
CCR8 1.6513 2.6862 CS, MT, CD
PRL 3.0052 2.5160 CCS, CD, CMO, GE
KCNE2 3.0052 2.4878 CMO
BCL2A1 1.0464 2.4271 CCS, CD
CASP1 1.3733 2.4146 CM, CD
CYP26B1 0.5734 2.4122 CD
WNT5A 0.0000 2.3095 CCS, CS, MT, CMO
CTBP2 1.0464 2.2869 CD
FZD1 1.0464 2.2815 CCS, CD
KCNJ10 0.5734 2.2685 CCS, CMO
CSTA 0.0000 2.2596 CD
PROC 1.3733 2.1991 CM, CCS, CD
FER 1.3733 2.1969 CM, CD
PTPRJ 0.0000 2.1933 CCS, CS, MT
LMO2 0.0000 2.1439 CMO
EMP1 1.6513 2.0746 CD
NKX3-1 0.0000 2.0678 CD
EEF1A2 1.6513 2.0260 CD
MLLT4 3.0052 2.0187 CCS
CLEC11A 0.7277  2.0197 CM, CD
CD1B 1.3733  2.0243 CCS
CD79B 0.7277  2.1431 CS, MT, CD
TWIST1 0.7277  2.1928 CD, CMO
ZCCHC2 0.0000  2.1962 CD
CAMK2D 3.0052  2.2123 CD
CD19 0.0000  2.2273 CCS, CS, MT, CD, CMO
CA9 2.5802  2.2440 CD
FERMT2 2.5802  2.2862 CCS
HES1 0.7277  2.3640 CD, CMO
AKT3 0.7277  2.3728 CD
(continued)
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Jurkat-Tat101 and Jurkat-Tat72 cells
Jurkat-Tat72 showed similar ability as control cells for
migrating in response to SDF-1a/CXCL12, but this
capacity was impaired in Jurkat-Tat101 (Figure 6A).
This chemotaxis impairment was also observed in
human peripheral blood lymphocytes (PBLs) from
healthy donors transiently transfected with Tat101 (data
not shown). This impairment was not due to a signiﬁcant
deﬁcient expression of CXCR4—the major receptor for
SDF-1a/CXCL12 (Figure 6B). Extracellular Tat can
inhibit SDF-1/CXCL12 signalling through binding to
CXCR4 (72) but Tat was not detected in the culture
medium of Jurkat-Tat101 or Jurkat-Tat72 as a soluble
form (data not shown). Basal and SDF-1a/
CXCL12-induced polarization capacity was also
measured in Jurkat-Tat101 and Jurkat-Tat72 in compari-
son with control cells by confocal microscopy after
staining with an antibody against ERM proteins
(Figure 6C), which are involved in the linking of
transmembrane proteins to the actin cytoskeleton (73).
More than 40% of Jurkat-Tat101 cells showed a basal
polarized morphology in the absence of chemoattractant
stimulus, in comparison with less than 10% of
polarized cells in both Jurkat-Tat72 and control cell
populations. Treatment of Jurkat-Tat101 with
SDF-1a/CXCL12 did not signiﬁcantly modify the
polarized morphology of these cells that seemed unable
to respond to the stimulus. These data correlate with the
chemotaxis impairment observed in Figure 6A. Analysis
by ﬂow cytometry after staining with phalloidin
conjugated to FITC showed that basal F-actin polymer-
ization was more than 10% increased in Jurkat-Tat101
(Figure 6D) and could not be further induced by
SDF-1a/CXCL12, in contrast with control cells.
Jurkat-Tat72 showed a moderate ability to respond to
SDF-1a/CXCL12.
Expression of cell surface receptors in Jurkat-Tat101
and Jurkat-Tat72 cells
Microarrays showed decrease of CD4 and CD1 (CD1a, b,
c, d, e) gene expression in both Jurkat-Tat101 and
Jurkat-Tat72. Parameters of statistical signiﬁcance were
fulﬁlled for all CD1 genes but not for CD4 gene, which
showed q-value >5%. However, analysis by RT–PCR of
mRNA expression for CD4 gene showed that it was
severely reduced in Jurkat-Tat101, as well as CD1
(Figure 7A). Flow cytometry analysis showed that CD4
and CD1a surface expression was greatly diminished in
Jurkat-Tat101 cells. CD4 surface expression in
Jurkat-Tat72 remained similar to control cells, but
CD1a diminished nearly 2-fold (Figure 7B and C). Both
CD4 and CD1a expression was annulled in both popula-
tions of Jurkat-Tat101, proving that those changes in CD4
expression were not due to random ﬂuctuations.
Moreover, treatment with doxycycline partially restored
CD4 and CD1a expression in Jurkat-Tat101 (data not
shown).
In silico modelling of Tat86 and Tat72 proteins
Lack of the second exon (29aa) could imply some struc-
tural rearrangements inside Tat protein that would explain
the functional and structural diﬀerences observed in
Jurkat-Tat72 in comparison with Jurkat-Tat101.
However, there are few studies about HIV-1 Tat crystal-
lization that could permit in silico modelling to evaluate
the eﬀect on Tat function after truncating the second
exon. PDB structure 1jfw corresponding to the NMR
spectra of a chemically synthesized Tat86 protein from
BRU isolate (66) has been used to develop a reliable
homology modelling of Tat72, with which shows
an identity of 91%. The absence of published structural
data for residues 86–101 makes impossible to perform
a reliable modelling of Tat101. Results from
modelling Tat72 showed that this protein is highly
ﬂexible and displays extended regions and connecting
loops, although it did not show highly deﬁned a-helixes
or b-sheets (Figure 8A). Tat72 model showed very
polarized electrostatic charges, with a high-positive
charged TAR-interacting region in the N-terminus,
whereas the C-terminus was severely reduced and
showed quite diminished positive charging (Figure 8B).
This end would likely interact with several host cell
proteins and structural targets, providing Tat101 with
29aa residues that would strength these interactions.
In order to infer the contribution of the second exon to
this interaction, modelling of Tat72/cyclin T1/TAR
complex was attempted. Because HIV-1 Tat structure
has not been crystallized in complex with TAR
and cyclin T1, a crystallization of Tat from equine infec-
tious anaemia virus (EIAV) in complex with TAR and
cyclin T1 (PDB structure 2w2h) was used as model (67).
Probably due to the high ﬂexibility of the protein, only
Table 1. Continued
Gene q-value
(%)
Fold
change
Biological function
WASF1 0.0000  2.3852 CD, CMO
NRP1 0.7277  2.4140 CM, CCS, CD, CMO
FZD3 0.7277  2.4699 CMO
DSP 0.7277  2.4781 CD
SMAD1 0.0000  2.8358 CMO
PPM1E 0.7277  2.8975 CMO
HTR2B 1.3733  2.8997 CD
TBC1D9 0.0000  3.3461 CD
PCSK5 0.0000  3.5028 CCS
PFN2 0.0000  3.8980 CMO
TPO 0.0000  4.5721 CCS
CD40LG 0.0000  7.0026 CM, CGP, CCS, CD,
CMO
NMNAT3 0.0000  7.5731 CD
Fold change expression values for genes deregulated in Jurkat-Tat101
versus control (Panel A) and Jurkat-Tat72 versus control (Panel B) are
listed according to higher (orange) and lower (green) expression. q-
value <5% was fulﬁlled by all genes and fold change was >2o r
< 2. Genes marked in blue represent those genes that are deregulated
in both comparisons. Biological functions in which these gene could be
involved are abbreviated as follows: CCS, Cell-to-Cell Signaling; CD,
Cell Death; CGP, Cell Growth and Proliferation; CM, Cell Movement;
CMO, Cell Morphology; CS, Cell Signaling; GE, Gene Expression;
MT, Molecular Transport; PTM, Postraductional Modiﬁcations.
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Figure 5. Changes in cell morphology and proliferation induced by Tat intracellular expression. (A) Relative cell size (forward scatter, FSC) and
complexity (sideward scatter, SSC) of Jurkat-Tat72 and Jurkat-Tat101 was analysed by ﬂow cytometry after staining with propidium iodide.
Representative SSC/FSC dot plots for each cell type were selected from three independent experiments. Percentage of cells inside the dot plot
upper right quadrant corresponds to cells with higher size and complexity than control cells. (B) Jurkat-Tat72 and Jurkat-Tat101 were analysed by
confocal microscopy after staining with an antibody against b-actin and a secondary antibody conjugated with Alexa 488. Cell diameter was
calculated in some selected cells. (C) Analysis of Jurkat-Tat101 by confocal microscopy after staining with a monoclonal antibody against Tat
and a secondary antibody conjugated with Alexa 488 conﬁrmed that cells with higher size were also expressing higher amounts of intranuclear Tat.
Dapi was used for nuclear staining. Cell diameter was measured in cells expressing high or low levels of Tat. (D) PHA-induced proliferation was
measured in both Jurkat-Tat72 and Jurkat-Tat101 in comparison with control cells. The histogram shows the fold-change mean of three diﬀerent
experiments and lines on the top of the bars represent the SD.
Nucleic Acids Research, 2010,Vol.38, No. 10 3299one a-helix interacting with TAR was resolved in
the structure 2w2h. EIAV and HIV-1 are distantly
related, with less that 30% sequence identity, but the
TAR interacting region is relatively conserved and
both human and horse cyclin T1 are almost identical.
EIAV TAR is formed by two distinct structural
regions and although the activation domains of both
HIV-1 and EIAV Tat contain a conserved core element,
the cysteine-rich domain is absent from EIAV Tat. As
a result, HIV-1 Tat requires the presence of additional
structural regions to completely fulﬁl its functions (20).
Based on this assumption, Tat72 was modelled using
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Figure 6. Impairment of cytoskeleton functions by the intracellular expression of Tat. (A) Analysis of SDF-1a/CXCL12-induced migration capacity
in Jurkat-Tat72 and Jurkat-Tat101 in comparison with control cells. Histogram shows the fold-change mean relative to three diﬀerent experiments
and lines on the top of the bars represent the SD. (B) Flow cytometry analysis of CXCR4 expression on the cell surface of Jurkat-Tat72 and
Jurkat-Tat101 after staining with a speciﬁc antibody conjugated with PE (line in bold). An antibody against whole IgG2a conjugated with PE was
used as isotype control (discontinuous line). (C) Jurkat-Tat72, Jurkat-Tat101 and control cells treated or not with SDF-1a/CXCL12 were adhered to
ﬁbronectin coverslips and stained with an antibody against ERM proteins and a secondary antibody conjugated with TexasRed. Images were
acquired by confocal microscopy and one representative experiment selected from three independent experiments is shown. Percentage of polarized
cells was determined by calculating the ratio between the number of polarized cells and the number of total cells counted in 15 diﬀerent microscope
ﬁelds. (D) Basal F-actin polymerization in Jurkat-Tat72 (red line) and Jurkat-Tat101 (blue line) was analysed by ﬂow cytometry after labelling with
phalloidin-FITC in comparison with control cells (black line). F-actin polymerization in response to SDF-1a/CXCL12 was also measured in control
cells (purple line), Jurkat-Tat72 and Jurkat-Tat101 (pink lines) using each cell background as basal control (black line). One representative exper-
iment selected from three independent experiments is shown.
3300 Nucleic Acids Research, 2010,Vol.38, No. 10as template ijfw structure except for the TAR-interacting
region, for which the resolved a-helix from 2w2h was
used (Figure 8C). Although 2w2h diﬀracting crystal was
generated by using a 57 residues-EIAV Tat (13-69aa) (67),
quite good volumetric ﬁtting in the space comprised
between TAR and cyclin T1 was obtained for Tat72
after slight manually adjustment to avoid molecular colli-
sions, despite 1jfw had been resolved in an unbound
conformation. Accordingly, folding of cyclin T1 around
Tat should be a highly conserved three-dimensional
structure. In this model, the C-terminal domain of Tat72
is deeply enfolded in the cyclin T1 structure, leaving no
physical space in the inner part of cyclin T1 for accom-
modating the C-terminus of 29aa that constitute the
second exon. This would imply that the second exon of
Tat101 in an extended conformation should be interacting
not only with the internal core of cyclin T1 but with its
external surface or with other protein/s bound to the
complex.
DISCUSSION
HIV-1 Tat acts in a diﬀerent way when it is synthesized
inside the cell during HIV-1 infection than when it is
released to the extracellular medium and taken up by
adjacent cells. As a secretable factor, Tat induces
dramatic cytoskeleton rearrangements (74) that lead to
apoptotic events related to HIV-1-induced pathogenesis
(6,43,44,75). As an intracellular protein, Tat is a regulator
involved in LTR transcriptional activation and HIV-1
replication (1). Despite the diﬀerent behaviour, the
protein structure is the same. Tat ﬁrst exon (1–72aa)
contains the minimal functional domain to generate a
protein competent in HIV-1 replication (20), whereas the
second exon (73–101aa) has often been described as dis-
pensable for Tat activity. However, most primate
lentiviruses conserve the second exon despite the high
error rate of the RT, suggesting it must have an essential
biological function (12,29,30,76–78). Moreover, an HIV
or SIV virus carrying one stop codon at the end of
the ﬁrst exon can spontaneously revert to full-length
Tat in vivo, yielding a more pathogenic virus (34,35).
This higher pathogenicity could be related to a higher eﬃ-
ciency for initiating the LTR transactivation or to
non-transcriptional activities. In order to study the role
of the second exon of Tat in the modiﬁcation of T-cell
functionality, two lines of Jurkat cells stably expressing
Tat101 or Tat72 have been obtained. Because the
86ESKKKVE
92 motif is critical for NF-kB transactivation
(28), it was assumed that Tat72 would be less eﬃcient to
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Figure 7. Expression of CD1 and CD4 in Jurkat-Tat72 and Jurkat-Tat101. (A) mRNA expression for CD1 (generic) and CD4 in Jurkat-Tat101 and
Jurkat-Tat72 was analysed by semiquantitative RT–PCR. b-actin gene was used as housekeeping gene. Gel bands were quantiﬁed by densitometry
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Nucleic Acids Research, 2010,Vol.38, No. 10 3301transactivate the HIV-1 LTR promoter in our cellular
system. This was conﬁrmed when Tat72 proved to be
25% less eﬃcient than Tat101 to initiate the
LTR-dependent transactivation. This lower activity was
related to lower NF-kB-, NF-AT- and Sp1-dependent
activities, in accordance with previous reports (79–84).
Due to Tat concentration in Jurkat-Tat101 and
Jurkat-Tat72 was very similar and highly stable after
long-term culture, diﬀerences in the transactivation
activity could not be caused by diﬀerent quantities of
Tat-expressing cells in each population. Therefore, Tat72
was less eﬃcient to transactivate the LTR but neverthe-
less, active.
The main activities attributed to Tat are the LTR
transactivation and the eﬃcient elongation of viral tran-
scripts, but other functions have also been related to Tat
as the modiﬁcation of the cytoskeleton dynamics
(6,12,14,43,44,75). The cytoskeleton integrity is indis-
pensable for maintaining the cellular shape and sur-
vival and for an appropriate immune response. Actually,
T cells become motile cells upon activation,
switching from a spherical to a polarized shape and ori-
enting their components towards one pole of the cell.
This mechanism relies on the cytoskeletal elements,
being the microﬁlament system remodelling essential
for T-cell polarization (85,86). It has been described that
extracellular Tat can induce dramatic cytoskeleton
rearrangements that lead to apoptosis (6,43,44,75).
Conversely, although the cytoskeleton can also be
greatly modiﬁed by Tat intracellular expression, these
changes do not decrease cell viability but even prevent
apoptosis induced by diﬀerent stimuli (14,17).
Accordingly, the role of intracellular Tat in the T-cell
cytoskeleton disorganization was investigated. To avoid
interferences caused by extracellular Tat, the possibility
that Tat could be solubilized in the culture medium of
Jurkat-Tat101 or Jurkat-Tat72 was previously ruled out.
A global functional analysis of changes in the T-cell
gene expression proﬁle induced by intracellular Tat and
the role of the second exon in these changes was per-
formed by using microarrays of whole human genome.
This wide approach has previously allowed the identiﬁca-
tion of cellular functions modiﬁed by the intracellular
expression of Tat, as those related to cell survival, prolif-
eration, transcription, immune response, metabolism and
chemokine release (36,87). De la Fuente et al. (88) also
determined that Tat86 deregulates many cellular genes
involved in cell signalling, translation and control of
A
B
C
Figure 8. Tat72 in silico modelling. (A) Tat72 (coloured ribbon:
N-terminus in blue, C-terminus in red) and Tat86 (magenta ribbon)
proteins were modelled using the PDB structure 1jfw according to
their ﬁtting in TAR/P-TEFb complex (theoretical bound conforma-
tion). Both proteins were highly ﬂexible and displayed extended
regions and connecting loops, although they did not show highly
deﬁned a-helixes or b-sheets. (B) Modelled Tat72 (surface view)
showed that the electrostatic charges were very polarized, with a
highly positive charged TAR-interacting region in the amino-terminal
extreme of the protein (dark blue) and a quite diminished positive
charging in the severely reduced C-terminal extreme (light blue). (C)
Modelling of Tat72 (surface view) in complex with cyclin T1/TAR was
attempted by using a crystallized EIAV Tat/cyclin T1/TAR complex
(PDB structure 2w2h). Tat72 was modelled using ijfw structure as
template except for the TAR-interacting region, for which a resolved
a-helix from 2w2h was used. The C-terminal interface of Tat72
perfectly adjusted inside the cyclin T1 structure, with quite good volu-
metric ﬁtting in the space comprised between TAR (orange) and cyclin
T1 (green), where CDK9 (pink) is bound to cyclin T1. Tat72 was
completely buried inside the cyclin T1 structure, with no space left
for accommodating the C-terminal domain of Tat101 (29aa).
3302 Nucleic Acids Research, 2010,Vol.38, No. 10proliferative and diﬀerentiation signals. However, Tat86
is a non-natural truncated form that lacks the
86ESKKKVE
92 motif critical for NF-kB transactivation
(28) and therefore, it should not be fully functional. In
fact, our results proved that Tat72 was not fully functional
either because the intracellular expression of Tat101
induced up- or down-regulation of nearly 300 genes,
whereas less than 70 genes were deregulated in
Jurkat-Tat72. Within these impaired functions, we
focused on those related to the cytoskeleton functionality
as cell morphology, growth and proliferation, movement
or apoptosis, as well as cell signalling and T-cell activa-
tion. All these functions are related to HIV-1 infectivity
and virulence. These data prove that although the second
coding exon of Tat may be dispensable for the
transcriptional activity of this protein, it is essential for
non-transcriptional functions.
Several functional analyses were performed to evaluate
the consequences of the gene expression deregulation
caused by intracellular Tat in the cytoskeleton activity
and the role of the second exon in these modiﬁcations.
First, we observed that intracellular Tat101 caused mod-
iﬁcations in the morphology and shape of Jurkat cells and
a strong inhibition of PHA-induced proliferation, whereas
Tat72 did not produce signiﬁcant changes. These results
were valuable because the role of Tat in cell proliferation
is controversial. Our data agree with previous reports that
demonstrate the inhibition of T-cell proliferation by
extracellular Tat (89–91), but in other studies Tat did
not show eﬀect on PHA-induced T-cell proliferation
(92,93). Moreover, Gibellini et al. (36) suggested that
Tat could be involved in the positive regulation of T-cell
proliferation, although no functional studies were per-
formed in this report. In our study, intracellular Tat101
not only caused the inhibition of PHA-induced prolifera-
tion but also of SDF-1/CXCL12-induced chemotaxis.
This inhibition was not observed in Jurkat-Tat72 either.
The chemotaxis impairment in Jurkat-Tat101 was not due
to changes in CXCR4 surface expression or to the binding
of extracellular Tat to CXCR4 (72) because soluble Tat
was not detected in the culture medium. Instead,
Tat-mediated mechanism underlying the impairment of
chemotaxis and proliferation could be related to the
deregulation of essential genes related to T-cell growth,
inﬁltration and development as CADM1 (94), Bcl11a
(95), or SMAD7—antagonist of TGF-b signalling (96).
Other genes related to migration were up-regulated
in Jurkat-Tat101 as DOCK3, which is involved in
cytoskeleton reorganization (97), modiﬁcation of cell mor-
phology (98), impairment of cell migration, and regulation
of the Wnt signalling pathway—related to cell growth,
proliferation and polarity (99–101). There are other
proteins required for cell motility that are down-regulated
as ELMO1 that acts together with DOCK1 and DOCK2
to activate Rac/Rho small GTPases (102,103). This mech-
anism could be similar to the Nef-dependent inhibition of
T-cell chemotaxis induced by the activation of Rac
through the binding of Nef to the complex DOCK2–
ELMO1 (103). Besides, intracellular Tat induced the
up-regulation of Spry2 -which can inhibit cell growth,
migration and invasion (104), as well as the
down-regulation of CD40LG, which modulates prolifera-
tion and movement (105), and CD44, which mediates
T-cell migration, recirculation and homing through
Rac-mediated cytoskeletal rearrangements (106). Other
receptors involved in cell migration as CCR1, CCR7
and MCAM/CD146 (107–109) were also down-regulated.
Within all these genes modiﬁed in Jurkat-Tat101, only
Wnt5a, Spry2 and CD40LG were also deregulated in
Jurkat-Tat72.
Impairment of chemotaxis and proliferation are related
to changes in the cytoskeleton structure mediated by Tat.
It has been demonstrated that extracellular Tat increases
the rate of tubulin polymerization in vitro (18,26). Now we
determined that intracellular Tat increased the rate of
basal F-actin polymerization in vivo and that this eﬀect
was dependent on the second exon. The higher basal
F-actin polymerization and polarization showed by
Jurkat-Tat101 could be responsible for the impairment
of migration because it would impede further response
to chemotactic stimuli. However, it has been described
that full-length Tat is not necessary to enhance the
tubulin polymerization that leads to apoptosis but only
peptides containing the glutamine-rich region are
required (18,26). These results were obtained by adding
high concentrations of exogenous Tat to an in vitro
system of puriﬁed lamb brain tubulin. Our results
indicated that the second exon was essential to induce
extensive modiﬁcations in the T-cell actin cytoskeleton
in vivo mediated by intracellular Tat. These modiﬁcations
can not be due exclusively to the direct interaction of Tat
with cytoskeleton elements as tubulin or actin but to other
indirect mechanisms as the up-regulation of DOCK3 and
Spry2 or the down-regulation of ELMO1, CD40LG and
CD44. These results increase the diﬀerences between the
behaviour of extra and intracellular Tat. Other possible
explanation is that Tat localizes predominantly in the
nucleus when is synthesized inside the cell, but it
remains mainly at the cytosol after being endocytosed
(17), where it could be retained through the binding to
cytoskeletal proteins as actin, tubulin, Lis1 and Hic
(19,110,111), causing higher toxicity.
Alterations in the cytoskeleton structure could impair
the HIV-1 infection because HIV-1 uses dynein and the
microtubule network to move towards the NPC (47).
Besides, the nucleocapsid core interacts with actin ﬁla-
ments to allow the intracellular transport of Gag, virus
assembly and budding (112), and actin and other
cytoskeletal proteins as ERM could act as structural com-
ponent of HIV-1 particles (113). These mechanisms could
mean that re-infection of cells already infected and
expressing intracellular Tat could be hindered. In fact,
Tat down-regulates surface receptors as CD4 (114) and
TCR/CD3 (115). Accordingly, Jurkat-Tat101 lacked of
several essential receptors on the cell surface. Absence of
CD4 and CCR9—an alternative receptor to CD4 (116) —
would also mean that these cells could not be re-infected.
Down-regulation of other surface receptors as CD1
(CD1a, b, c, d, e) and CD2 was also dramatic in
Jurkat-Tat101. It has been described that endogenous
HIV-1 Nef down-regulates CD1a selectively among CD1
molecules in dendritic cells (117), but we observed that
Nucleic Acids Research, 2010,Vol.38, No. 10 3303intracellular Tat101 down-regulated all CD1 molecules
in Jurkat. Because CD1 receptors act as antigen presenting
molecules (118), their down-regulation would contribute
to the impairment of the immune response. In fact, Tat
has been described as an inhibitor of antigen-speciﬁc
responsiveness of T cells, inducing anergy (93).
Down-regulation of these receptors was dependent on
the second exon because it was not observed in
Jurkat-Tat72.
In summary, Tat second exon was responsible for
altering the cytoskeleton structure and functions as
proliferation, chemotaxis and migration, and for the
down-expression of surface receptors, when Tat is
synthesized inside the cell. These changes suggest that
intracellular Tat could be essential for adapting the host
cell to HIV-1 infection, for hindering re-infections, and for
the impairment of T-cell functionality during the immune
response. Structurally, the second exon is a high-positive
charged region of 29aa that would likely enhance the
binding strength or aﬃnity to host cell proteins and struc-
tural targets, as was described for the HIV-2 Tat second
exon (119–121). To test this statement, in silico modelling
of Tat72 was performed and adjusted within the Tat/
TAR/P-TEFb complex, leaving Tat72 C-terminus deeply
buried in the cyclin T1 structure. It would be improbable
to ﬁt Tat101 in the same space, implying that the
C-terminal domain must interact not only with the
internal core of cyclin T1 but with its external surface.
Accordingly, the presence of the second exon would
explain why Tat101 was more competent than Tat72 to
cause gene expression deregulation and cytoskeleton
modiﬁcations. More analyses will be necessary to
evaluate how these changes in the cytoskeleton structure
and functionality would aﬀect HIV-1 infection. Data
obtained by microarrays provide important clues about
the pathways impaired by Tat and will be used as the
basis for more extensive studies.
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